As the need for hematology and immunoassay testing grows exponentially, Indexus Biomedical is developing a multi-function blood analyzer on a single, low-cost platform to enable earlier detection and treatment. Under the sponsorship of the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID), Indexes Biomedical is developing the menu of tests specifically to facilitate advanced diagnostic healthcare at the primary care level for HIV infected patients. In the future, the platform can also be used to diagnose cancers and identify risk factors for cardiac, kidney and liver diseases.

Recognizing the need for a better solution, NIH, NIAID, the North Carolina Department of Commerce and a wide network of advisors and team members spread across the United States, are supporting the company’s mission.

“No one should be deprived of life-saving medical technologies because of cost or lack of access. I believe that we can dramatically change the paradigm of how technologies are made available to people by synergistically combining multiple solutions through innovations in systems engineering and developing new solutions in a holistic way,” says Indexes Biomedical CEO and CTO Chiranjit Deka. “This will reduce cost and improve access. HOW a solution is served can make more impact than WHAT the underlying technologies are.”

Indexus Biomedical is gaining accolades for its innovation in patent-pending technologies. In 2014, they were awarded Phase I-Small Business Innovative Research (SBIR) from NIH/NIAID and received a SBIR Matching Fund in 2015.